The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation
Tóm tắt
The physiological regulation of the immune system encompasses comprehensive anti‐inflammatory mechanisms that can be harnessed for the treatment of infectious and inflammatory disorders. Recent studies indicate that the vagal nerve, involved in control of heart rate, hormone secretion and gastrointestinal motility, is also an immunomodulator. In experimental models of inflammatory diseases, vagal nerve stimulation attenuates the production of proinflammatory cytokines and inhibits the inflammatory process. Acetylcholine, the principal neurotransmitter of the vagal nerve, controls immune cell functions via the alpha7 nicotinic acetylcholine receptor (alpha7nAChR). From a pharmacological perspective, nicotinic agonists are more efficient than acetylcholine at inhibiting the inflammatory signaling and the production of proinflammatory cytokines. This ‘nicotinic anti‐inflammatory pathway’ may have clinical implications as treatment with nicotinic agonists can modulate the production of proinflammatory cytokines from immune cells. Nicotine has been tested in clinical trials as a treatment for inflammatory diseases such as ulcerative colitis, but the therapeutic potential of this mechanism is limited by the collateral toxicity of nicotine. Here, we review the recent advances that support the design of more specific receptor‐selective nicotinic agonists that have anti‐inflammatory effects while eluding its collateral toxicity.
Từ khóa
Tài liệu tham khảo
Abraham E, 1998, Double‐blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. vNORASEPT II Study Group, Lancet, 351, 929, 10.1016/S0140-6736(05)60602-2
Lloyd GK, 2000, Neuronal nicotinic acetylcholine receptors as novel drug targets, J Pharmacol Exp Ther, 292, 461
Lukas RJ, 1999, International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits, Pharmacol Rev, 51, 397
Meyer EM, 1998, Analysis of 3‐(4‐hydroxy, 2‐Methoxybenzylidene)anabaseine selectivity and activity at human and rat alpha‐7 nicotinic receptors, J Pharmacol Exp Ther, 287, 918
Papadopoulos NG, 2005, Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients?, Clin Exp Rheumatol, 23, 861
Rangwala F, 1997, Neuronal alpha‐bungarotoxin receptors differ structurally from other nicotinic acetylcholine receptors, J Neurosci, 17, 8201, 10.1523/JNEUROSCI.17-21-08201.1997
Schwartz SL, 1976, Interaction of nicotine and other amines with the endocytic and exocytic functions of macrophages, Fed Proc, 35, 85
Schwartz SL, 1972, Inhibition of pinocytosis by nicotine, J Pharmacol Exp Ther, 183, 370
Shaw S, 2003, Angiotensin II blocks nicotine‐mediated neuroprotection against beta‐amyloid (1‐42) via activation of the tyrosine phosphatase SHP‐1, J Neurosci, 23, 11224, 10.1523/JNEUROSCI.23-35-11224.2003
Theodorou V, 1996, Integrative neuroimmunology of the digestive tract, Vet Res, 27, 427
Thyberg J, 1983, Effects of nicotine on the fine structure of cultivated mouse peritoneal macrophages, Acta Pathol Microbiol Immunol Scand [A], 91, 23
Van Assche G, 2005, Medical treatment of inflammatory bowel diseases, Curr Opin Gastroenterol, 21, 443